{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:59:22Z","timestamp":1785455962584,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U01-AI069924-05"],"award-info":[{"award-number":["5U01-AI069924-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32FP30-189498"],"award-info":[{"award-number":["32FP30-189498"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825 162"],"award-info":[{"award-number":["825 162"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jval.2026.03.2245","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:40:26Z","timestamp":1776814826000},"page":"1434-1442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions"],"prefix":"10.1016","volume":"29","author":[{"given":"Tasnim","family":"Hamza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Chalkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Lorscheider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pletscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jval.2026.03.2245_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/0272989X13487257","article-title":"Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost-effectiveness analysis","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Mak"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2245_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/13696998.2019.1588737","article-title":"Cost-effectiveness analyses using real-world data: an overview of the literature","volume":"22","author":"Bowrin","year":"2019","journal-title":"J Med Econ"},{"issue":"15","key":"10.1016\/j.jval.2026.03.2245_bib3","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/sim.6883","article-title":"Testing moderation in network meta-analysis with individual participant data","volume":"35","author":"Dagne","year":"2016","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2245_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0962280216660741","article-title":"An overview of methods for network meta-analysis using individual participant data: when do benefits arise?","volume":"27","author":"Debray","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"20","key":"10.1016\/j.jval.2026.03.2245_bib5","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/sim.6519","article-title":"Incorporation of individual-patient data in network meta-analysis for multiple continuous endpoints, with application to diabetes treatment","volume":"34","author":"Hong","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2026.03.2245_bib6","author":"Phillippo"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2245_bib7","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/sim.8859","article-title":"Comparing methods for estimating patient-specific treatment effects in individual patient data meta-analysis","volume":"40","author":"Seo","year":"2021","journal-title":"Stat Med"},{"issue":"20","key":"10.1016\/j.jval.2026.03.2245_bib8","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1002\/sim.9034","article-title":"A two-stage prediction model for heterogeneous effects of treatments","volume":"40","author":"Chalkou","year":"2021","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0272989X221143058","article-title":"Decision curve analysis for personalized treatment choice between multiple options","volume":"43","author":"Chalkou","year":"2023","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib11","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg","year":"2012","journal-title":"Pharm Ther"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2245_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2245_bib13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2245_bib14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WCO.0000000000000206","article-title":"Classification, diagnosis, and differential diagnosis of multiple sclerosis","volume":"28","author":"Katz Sand","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"7549","key":"10.1016\/j.jval.2026.03.2245_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/520609a","article-title":"Personalized medicine: time for one-person trials","volume":"520","author":"Schork","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jval.2026.03.2245_bib17","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/psp4.12715","article-title":"Heterogeneous treatment effect analysis based on machine-learning methodology","volume":"10","author":"Gong","year":"2021","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.jval.2026.03.2245_bib18","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"36","author":"Kent","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2245_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12874-020-01145-1","article-title":"Predictive approaches to heterogeneous treatment effects: a scoping review","volume":"20","author":"Rekkas","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2245_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12874-019-0817-6","article-title":"Statistical approaches to identify subgroups in meta-analysis of individual participant data: a simulation study","volume":"19","author":"Belias","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2245_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2026.03.2245_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-6-18","article-title":"Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis","volume":"6","author":"Hayward","year":"2006","journal-title":"BMC Med Res Methodol"},{"issue":"7016","key":"10.1016\/j.jval.2026.03.2245_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.311.7016.1356","article-title":"An evidence based approach to individualising treatment","volume":"311","author":"Glasziou","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2245_bib24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jclinepi.2013.02.009","article-title":"A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research","volume":"66","author":"Varadhan","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2245_bib25","first-page":"2075","article-title":"Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials","volume":"45","author":"Kent","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2245_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/CIRCOUTCOMES.113.000497","article-title":"Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials","volume":"7","author":"Burke","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jval.2026.03.2245_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1745-6215-11-85","article-title":"Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal","volume":"11","author":"Kent","year":"2010","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2245_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bju.12802","article-title":"Baseline characteristics predict risk of progression and response to combination medical therapy for benign prostatic hyperplasia","volume":"115","author":"Kozminski","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.jval.2026.03.2245_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h454","article-title":"Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program","volume":"350","author":"Sussman","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2245_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1162\/rest_a_00732","article-title":"Endogenous stratification in randomized experiments","volume":"100","author":"Abadie","year":"2018","journal-title":"Rev Econ Stat"},{"key":"10.1016\/j.jval.2026.03.2245_bib31","series-title":"Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2008"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2245_bib32","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jclinepi.2004.01.020","article-title":"Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example","volume":"57","author":"Moons","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"28","key":"10.1016\/j.jval.2026.03.2245_bib33","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/sim.5442","article-title":"Mixed treatment comparisons using aggregate and individual participant level data","volume":"31","author":"Saramago","year":"2012","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2245_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jrsm.1292","article-title":"Graphs of study contributions and covariate distributions for network meta-regression","volume":"9","author":"Donegan","year":"2018","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jval.2026.03.2245_bib35","series-title":"Network Meta-Analysis for Decision Making","first-page":"227","year":"2018"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2245_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40273-021-01023-8","article-title":"Cost effectiveness and budget impact of siponimod compared to interferon beta-1a in the treatment of adult patients with secondary progressive multiple sclerosis with active disease in Switzerland","volume":"39","author":"Schur","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2245_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0272989X06297393","article-title":"Value of information on preference heterogeneity and individualized care","volume":"27","author":"Basu","year":"2007","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2245_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jval.2011.07.015","article-title":"The role of the expected value of individualized care in cost-effectiveness analyses and decision making","volume":"15","author":"van Gestel","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2245_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41512-021-00106-6","article-title":"Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis","volume":"5","author":"Chalkou","year":"2021","journal-title":"Diagn Progn Res"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152347","article-title":"SMSC Scientific Board The Swiss Multiple Sclerosis Cohort-Study (SMSC): a prospective Swiss wide investigation of key phases in disease evolution and new treatment options","volume":"11","author":"Disanto","year":"2016","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2245_bib41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40120-021-00264-1","article-title":"How have economic evaluations in relapsing multiple sclerosis evolved over time? A systematic literature review","volume":"10","author":"Wiyani","year":"2021","journal-title":"Neurol Ther"},{"issue":"2_suppl","key":"10.1016\/j.jval.2026.03.2245_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1352458517708685","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for Switzerland","volume":"23","author":"Calabrese","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2245_bib44","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/hec.804","article-title":"Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach","volume":"13","author":"Cooper","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2245_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/0272989X13481110","article-title":"Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons","volume":"5","author":"Hong","year":"2013","journal-title":"Med Decis Mak"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2245_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jrsm.1619","article-title":"Synthesizing cross-design evidence and cross-format data using network meta-regression","volume":"14","author":"Hamza","year":"2023","journal-title":"Res Synth Methods"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2245_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128804","article-title":"Exploring treatment by covariate interactions using subgroup analysis and meta-regression in cochrane reviews: a review of recent practice","volume":"10","author":"Donegan","year":"2015","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2245_bib49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","article-title":"Using cost-effectiveness analysis to address health equity concerns","volume":"20","author":"Cookson","year":"2017","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2245_bib50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/jpm7030010","article-title":"Value-based pricing and reimbursement in personalised healthcare: introduction to the basic health economics","volume":"7","author":"Garrison","year":"2017","journal-title":"J Pers Med"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2245_bib51","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","article-title":"Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States","volume":"19","author":"Mauskopf","year":"2016","journal-title":"J Med Econ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:20:01Z","timestamp":1785453601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526023909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1098301526023909"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2245","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}